-
公开(公告)号：EP4282986A3
公开(公告)日：2024-02-28
申请号：EP23199877.4
申请日：2018-03-23
IPC分类号： C12Q1/6888 , C12Q1/70
摘要： There is disclosed a composition or kit comprising at least a first HPIV-2 amplification oligomer and a second HPIV-2 amplification oligomer, wherein: the first HPIV-2 amplification oligomer and second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700.
-
公开(公告)号：EP4279613A2
公开(公告)日：2023-11-22
申请号：EP23200155.2
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit for detecting two or more of HPIV-1, HPIV-2, HPIV-3 or HPIV-4 comprising two or more first and second amplification oligomers selected from: (A) first and second HPIV-1 amplification oligomers; (B) first and second HPIV-2 amplification oligomers; (C) first and second HPIV-3 amplification oligomers; and (D) first and second HPIV-4 amplification oligomers, wherein (A) the first HPIV-1 amplification oligomer and the second HPIV-1 amplification oligomer is configured to amplify an HPIV-1 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-1 position located within HPIV-1 positions 330-490 or 960-1100; (B) the first HPIV-2 amplification oligomer and the second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length and comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700; (C) the first HPIV-3 amplification oligomer and the second HPIV-3 amplification oligomer are configured to amplify an HPIV-3 amplicon of at least about 50 nucleotides in length comprising at least one Human Parainfluenza Virus 3 (HPIV-3) position located in the range of positions 1295-1305, 1350-1360, and/or 1380-1390; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1270 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355, and the first and second HPIV-3 amplification oligomers are configured to produce an HPIV-3 amplicon; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1437, and the first and second amplification oligomers are configured to produce an HPIV-3 amplicon; or (D) the first HPIV-4 amplification oligomer and second HPIV-4 amplification oligomer are configured to amplify an HPIV-4 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-4 position located within HPIV-4 positions 620-740, 2130-2410, 2520-3040, or 10090-11980.
-
公开(公告)号：EP4219770A3
公开(公告)日：2023-08-16
申请号：EP23159203.1
申请日：2018-03-23
摘要： A kit for analysis of a Respiratory Syncytial Virus B (RSV B) target nucleic acid molecule species that may be present in a biological sample, comprising: an RSV B primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 &115.
-
公开(公告)号：EP3601617A1
公开(公告)日：2020-02-05
申请号：EP18716844.8
申请日：2018-03-23
IPC分类号： C12Q1/6888 , C12Q1/70
-
公开(公告)号：EP1877581A2
公开(公告)日：2008-01-16
申请号：EP06752336.5
申请日：2006-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6813 , C12Q1/6834 , Y10T436/143333 , C12Q2537/125 , C12Q2523/113 , C12Q2565/519 , C12Q2527/101
摘要： Methods for efficiently capturing a target nucleic acid from a sample by using a mixture that contains a capture probe specific for the target nucleic acid, the target nucleic acid, and a denaturant chemical, which mixture is incubated at elevated temperature for a short time, are disclosed. Compositions that include a capture probe that specifically binds to a target nucleic acid and a denaturant chemical, which when mixed with the target nucleic acid and incubated at elevated temperature for a short time, promote efficient hybridization of the capture probe and target nucleic acid are disclosed.
-
公开(公告)号：EP4282986A2
公开(公告)日：2023-11-29
申请号：EP23199877.4
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit comprising at least a first HPIV-2 amplification oligomer and a second HPIV-2 amplification oligomer, wherein: the first HPIV-2 amplification oligomer and second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700.
-
公开(公告)号：EP4219770A2
公开(公告)日：2023-08-02
申请号：EP23159203.1
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： A kit for analysis of a Respiratory Syncytial Virus B (RSV B) target nucleic acid molecule species that may be present in a biological sample, comprising: an RSV B primer pair for generating an RSV B amplicon if RSV B is present in the biological sample, the RSV B primer pair comprising a first RSV B primer and a second RSV B primer, wherein: (i) the first RSV B primer is substantially complementary to a first RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS:99 to 101 and 106; and (ii) the second RSV B primer is substantially complementary to a second RSV B target nucleic acid sequence, is about 17 to about 100 contiguous bases in length, and comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NOS: 104 to 106 &115.
-
公开(公告)号：EP4219768A2
公开(公告)日：2023-08-02
申请号：EP23156298.4
申请日：2018-03-23
IPC分类号： C12Q1/70
摘要： There is disclosed a composition or kit comprising at least first and second amplification oligomers, wherein the first amplification oligomer and the second amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159.
-
公开(公告)号：EP1877581B1
公开(公告)日：2012-03-28
申请号：EP06752336.5
申请日：2006-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6813 , C12Q1/6834 , Y10T436/143333 , C12Q2537/125 , C12Q2523/113 , C12Q2565/519 , C12Q2527/101
摘要： Methods for efficiently capturing a target nucleic acid from a sample by using a mixture that contains a capture probe specific for the target nucleic acid, the target nucleic acid, and a denaturant chemical, which mixture is incubated at elevated temperature for a short time, are disclosed. Compositions that include a capture probe that specifically binds to a target nucleic acid and a denaturant chemical, which when mixed with the target nucleic acid and incubated at elevated temperature for a short time, promote efficient hybridization of the capture probe and target nucleic acid are disclosed.
-
公开(公告)号：EP4279613A3
公开(公告)日：2024-05-22
申请号：EP23200155.2
申请日：2018-03-23
IPC分类号： C12Q1/6888 , C12Q1/70
CPC分类号： C12Q1/6888 , C12Q1/701
摘要： There is disclosed a composition or kit for detecting two or more of HPIV-1, HPIV-2, HPIV-3 or HPIV-4 comprising two or more first and second amplification oligomers selected from: (A) first and second HPIV-1 amplification oligomers; (B) first and second HPIV-2 amplification oligomers; (C) first and second HPIV-3 amplification oligomers; and (D) first and second HPIV-4 amplification oligomers, wherein (A) the first HPIV-1 amplification oligomer and the second HPIV-1 amplification oligomer is configured to amplify an HPIV-1 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-1 position located within HPIV-1 positions 330-490 or 960-1100; (B) the first HPIV-2 amplification oligomer and the second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 amplicon of at least about 50 nucleotides in length and comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700; (C) the first HPIV-3 amplification oligomer and the second HPIV-3 amplification oligomer are configured to amplify an HPIV-3 amplicon of at least about 50 nucleotides in length comprising at least one Human Parainfluenza Virus 3 (HPIV-3) position located in the range of positions 1295-1305, 1350-1360, and/or 1380-1390; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1270 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355, and the first and second HPIV-3 amplification oligomers are configured to produce an HPIV-3 amplicon; or the first HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355 and the second HPIV-3 amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1437, and the first and second amplification oligomers are configured to produce an HPIV-3 amplicon; or (D) the first HPIV-4 amplification oligomer and second HPIV-4 amplification oligomer are configured to amplify an HPIV-4 amplicon of at least about 50 nucleotides in length comprising at least one HPIV-4 position located within HPIV-4 positions 620-740, 2130-2410, 2520-3040, or 10090-11980.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.015 秒)
